Samsung Biologics said on the 13th that it signed a contract for contract manufacturing (CMO) of pharmaceuticals worth about 280 billion won with a Europe-based drugmaker.
The contract was signed in Aug. last year, but at the time it did not meet the disclosure threshold under the contract terms, so no separate filing was made. Afterward, as the contract terms were fulfilled, the minimum purchase quantity was confirmed, leading to the filing on this day.
The counterparty will not be disclosed until 2032 under a confidentiality clause for business operations. The size of the contract is equivalent to 6.15% of Samsung Biologics' 2024 revenue.
※ This article has been translated by AI. Share your feedback here.